CN107011336A - One class is using pyridine as the pH fluorescence probes and its application for protonating site - Google Patents
One class is using pyridine as the pH fluorescence probes and its application for protonating site Download PDFInfo
- Publication number
- CN107011336A CN107011336A CN201710187200.6A CN201710187200A CN107011336A CN 107011336 A CN107011336 A CN 107011336A CN 201710187200 A CN201710187200 A CN 201710187200A CN 107011336 A CN107011336 A CN 107011336A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- represent
- alkyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000523 sample Substances 0.000 title claims abstract description 112
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 32
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 21
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims abstract description 20
- 125000005843 halogen group Chemical group 0.000 claims abstract description 16
- -1 methoxyl group Chemical group 0.000 claims abstract description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 12
- 239000004305 biphenyl Substances 0.000 claims abstract description 10
- 235000010290 biphenyl Nutrition 0.000 claims abstract description 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 9
- 238000001514 detection method Methods 0.000 claims abstract description 8
- 230000008569 process Effects 0.000 claims abstract description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000003222 pyridines Chemical class 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 9
- 238000007363 ring formation reaction Methods 0.000 claims description 9
- HDWLUGYOLUHEMN-UHFFFAOYSA-N Dinobuton Chemical group CCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1OC(=O)OC(C)C HDWLUGYOLUHEMN-UHFFFAOYSA-N 0.000 claims description 8
- 241000425573 Talanes Species 0.000 claims description 8
- 239000008346 aqueous phase Substances 0.000 claims description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 7
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 6
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 5
- 229910019213 POCl3 Inorganic materials 0.000 claims description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 238000000799 fluorescence microscopy Methods 0.000 claims description 3
- 239000004593 Epoxy Substances 0.000 claims description 2
- 238000007259 addition reaction Methods 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 230000017858 demethylation Effects 0.000 claims description 2
- 238000010520 demethylation reaction Methods 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 4
- 150000001555 benzenes Chemical class 0.000 claims 3
- HGEXVTDKVHLPRZ-UHFFFAOYSA-N 5-phenyl-2-pyridin-4-yl-1,3-oxazole Chemical compound C=1N=C(C=2C=CN=CC=2)OC=1C1=CC=CC=C1 HGEXVTDKVHLPRZ-UHFFFAOYSA-N 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 239000004327 boric acid Substances 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical group OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims 1
- 125000004969 haloethyl group Chemical group 0.000 claims 1
- 125000003011 styrenyl group Chemical class [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 abstract description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 5
- 238000012800 visualization Methods 0.000 abstract description 2
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 230000008859 change Effects 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000002189 fluorescence spectrum Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 238000002601 radiography Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical class BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- LZKYUWXZSBYMSA-UHFFFAOYSA-N 4-bromo-2,5-dimethylphenol Chemical class CC1=CC(Br)=C(C)C=C1O LZKYUWXZSBYMSA-UHFFFAOYSA-N 0.000 description 1
- UYGBSRJODQHNLQ-UHFFFAOYSA-N 4-hydroxy-3,5-dimethylbenzaldehyde Chemical class CC1=CC(C=O)=CC(C)=C1O UYGBSRJODQHNLQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 0 C*(*)c(cc1)ccc1N(*)C(C)(C)c1c(*)cc(*c(cc2)ccc2C(OC(c2ccncc2)=*=C)=CC)cc1* Chemical compound C*(*)c(cc1)ccc1N(*)C(C)(C)c1c(*)cc(*c(cc2)ccc2C(OC(c2ccncc2)=*=C)=CC)cc1* 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 1
- JLGLQAWTXXGVEM-UHFFFAOYSA-N triethylene glycol monomethyl ether Chemical compound COCCOCCOCCO JLGLQAWTXXGVEM-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
- C09K2211/1033—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with oxygen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
The present invention relates to detection technique field, more particularly to noval chemical compound of the class that represents of logical formula (I) using 4 (oxazolyl of 5 phenyl 2) pyridines as core texture, wherein { R1、R2And R3Represent halogen atom, hydrogen atom, alkyl, alkoxy or with following formula (IA) group [in formula, Y represent methylene, oxygen atom or nitrogen-atoms and following formula (IB) expression group (in formula, R5Represent hydrogen atom, alkyl or alkoxy;Z1、Z2And Z3Represent no or oxygen atom;N, o and p represent 0,1 or 2) are covalently attached the group formed;R4Represent hydrogen atom, methyl, methoxyl group or the group represented with following formula (IB);M represents 0,1 or 2], R1、R2And R3Can not be halogen atom, hydrogen atom, alkyl or alkoxy simultaneously, X represents CH=CH or not had (i.e. biphenyl structural) }, further relate to its chemical preparating process, its detection as fluorescence probe to pH value in the aqueous solution, and the detection of its pH value in the cell, especially the fluoroscopic visualization of cell, waits the application purpose of many occasions.
Description
【Technical field】
It is more particularly to a kind of to be used for the fluorescence probe of pH value in specific detection aqueous phase the present invention relates to detection technique field
And preparation method thereof and the fluorescence probe living biological cell detection in application.
【Background technology】
It is many important physiology courses of pH value and cell, enzyme and tissue such as cell propagation and apoptosis in human body cell, a variety of
The activities such as drug resistance, ion transport, endocytosis and contraction of muscle are all closely related.Pass through gap connection and signal path
Change, pH change also affects the nervous system activities such as cynapse transmission, neuronal excitability and iuntercellular coupling.Not just
Normal cell function, growth and divide generally directly or indirectly relevant with abnormal pH value, and easily trigger as cancer and Ah
The diseases such as Er Cihaimo syndromes.
Under normal circumstances, the normal value of hydrionic concentration is 7.4 in 40nmol/L or so, i.e. pH in cell liquid, greatly
It there are about 5nmol/L variation (pH 7.35-7.45).The fluctuation up and down of 0.1-0.2 pH unit this may result in cardiopulmonary and nerve
The disease of system, such as Alzheimer syndrome, serious possibly even threat to life.The optimal pH value of human body is in 7.35-
7.45 or so, in alkalescent, because cytoactive at this moment is most strong, organ operation is most normal.If value is less than this value, human body
The activity of cell, various enzymes and hormone will greatly be suppressed, and cause tissue organ function to decline, human immunity reduction etc.,
Various diseases can be triggered, such as:1) human body cell is made to undergo mutation and aging;2) acidic materials are easily accumulated in the blood vessels, are formed
Fatty liver, high fat of blood, gout simultaneously trigger other cardiovascular and cerebrovascular diseases;3) human body value often declines 0.1 unit, and insulin utilization rate is just
Decline 30%, easily produce diabetes with triggering complication;4) acidic constitution can also make one internal free radical substantial increase, no
Beneficial to the absorption of calcium, osteoporosis is caused;5) it is easily caused canceration.Tumor cell viability is most strong in pH value 6.8-6.95, and
Also it could must be shifted in acid condition, so acidic constitution is the main cause for producing cancer, while it can make one
The function reduction 25% or so of body immunocyte, greatly weakens the ability to inhibiting tumor cell.In addition, having inside some organelles
It is normal be acidity, between 4-6, such as endosome and Vacuoles of Plants.In cell biology, when pH value is 7.0, albumen
Qualitative change or the effect of enzyme and protein function are slow, and low ph value, which can be played, makes protein denaturation or kinase and protein function
Effect.For example, the sour environment (pH 4.5-5.5) in lysosome, can promote drop of the protein in cellular process
Solution.Therefore cell dysfunction is often extremely relevant with pH value in organelle.
At present, many methods can be used for detection pH.Such as microelectrode, nuclear-magnetism, absorption and fluorescence spectrum method.In these sides
In method, fluorescence method is being determined due to the property of its non-intrusive, high sensitivity and selectivity, and widely available fluorescent dye
It is more more superior than other method during pH.Moreover, Induced Fluorescence Microscopy can capture cell by using fluorescent pH probe
Interior hydrionic time-space resolution.
Generally, two classes are more suitable for the report of the pH fluorescence probes of different pH scopes.One class probe a (J as follows
Am Chem Soc.2007;129:1894-1895) with b (Org Lett. 2004;6:2757-2760) it is used in cytoplasm,
Suitable for pH scopes in 6.80-7.40, an also class such as probe c (New J Chem.2010;34:656), it is used for acid thin
The use of pH scopes is 4.50-6.00 in born of the same parents' device (such as lysosome).
However, almost not on suitable for (pH under the acid condition of pole<4) research of pH probes.Although most of work
Species can hardly survive under conditions of highly acidic, but substantial amounts of microorganism such as acidophilia bacterium, enteropathogen and
Helicobacter pylori misses potter severe sour environment.Therefore, develop effective suitable for being detected under high acid condition
The pH fluorescence probes of intracellular ph value are highly significant and practical value.
【The content of the invention】
The problem of the present invention is to provide has larger dissolubility and can be as highly sensitive pH fluorescence in aqueous phase
Probe and the compound being used.Specifically, problem of the invention is to provide a kind of compound, and the compound can be in water
Complex compound differs more obvious with the fluorescent characteristic of the compound before complexing and has rule after specific capture hydrogen ion in phase, seizure
Rule, can be used as pH fluorescence probes.Furthermore, the other problem of the present invention is to provide containing as characterized above
Compound pH fluorescence probes and using the pH fluorescence probes aqueous phase in pH value assay method.
Present inventor is in order to solve above-mentioned problem, by research, it was found that using 4- (2- oxazolyls) pyridine as substituent
Compound has high specificity to hydrogen ion, captures hydrogen ion, and the fluorescent characteristic of complex compound has obvious change before not being complexed
Change.Present inventor further study show that, it was found that the compound represented with following logical formula (I)s can rapidly form with hydrogen from
Significant change occurs for the complex compound of son, fluorescent characteristic.In addition flexible group in compound as shown in formula (IA) is very big to be increased
Strong dissolubility of the compound in aqueous phase, significantly increases its actual application value that pH value is detected in aqueous phase.
That is, the invention provides the compound represented with following logical formula (I)s:
In formula, R1、R2And R3Separately represent halogen atom, hydrogen atom, alkyl, alkoxy or with following formula (IA)
Group
[in formula, m represents 0,1 or 2, R4Represent hydrogen atom, alkyl, alkoxy or the base represented with following formula (IB)
Group;Y represents the group for the formation that the group that methylene, oxygen atom or nitrogen-atoms and following formula (IB) are represented is connected
(in formula, R5Represent hydrogen atom, alkyl or alkoxy;Z1、Z2And Z3Separately represent that no or oxygen is former
Son, n, o and p separately represent that 0,1 or 2), Y represent what methylene, oxygen atom or nitrogen-atoms and formula (IB) were represented
The group for the formation that group is connected], R1、R2And R3Can not be halogen atom, hydrogen atom, alkyl or alkoxy simultaneously;X is represented
CH=CH (i.e. with both sides phenyl ring formation talan structure) does not have (being biphenyl structural) }.
As the preferred mode of foregoing invention, there is provided the compound represented with following logical formula (II)s
In formula, R6And R7Separately represent halogen atom, hydrogen atom, alkyl or alkoxy;R8Expression hydrogen atom,
Alkyl or alkoxy;X1Represent CH=CH (i.e. with both sides phenyl ring formation talan structure) or do not have (to be biphenyl knot
Structure).According to the preferred embodiment of the present invention, R can be provided6And R7It is simultaneously methyl, R8It is the compound of methoxyl group.
In addition, according to the present invention it is possible to providing the compound represented with following logical formula (III)s
[in formula, R9And R10Separately represent halogen atom, hydrogen atom, alkyl or alkoxy;R11And R12Independently
Ground represents hydrogen atom, alkyl, alkoxy or the group represented with following formula (IIIA)
(in formula, R13Represent hydrogen atom, alkyl or alkoxy;Z4、Z5And Z6Separately represent that no or oxygen is former
Son, r, s and t separately represent 0,1 or 2), X2Represent CH=CH (i.e. with both sides phenyl ring formation talan structure)
Or there is no (being biphenyl structural);Q represents 1 or 2].According to preferred embodiment of the present invention, R can be provided9And R10It is simultaneously
Hydrogen atom, R13For the compound of methoxyl group.
More, according to the present invention it is possible to provide what is represented containing above-mentioned logical formula (I), logical formula (II) or logical formula (III)
The pH fluorescence probes of compound;And the compound that is represented by above-mentioned logical formula (I), logical formula (II) or logical formula (III) and hydrogen from
The complex compound that son is formed.The pH fluorescence probes can be used for determining the pH value in strongly acidic aqueous solution, cell and tissue.
Further, according to the present invention, the assay method of pH value in aqueous phase can be both provided, also providing will be led to above-mentioned
The compound that formula (I), logical formula (II) or logical formula (III) are represented is used as the method for pH fluorescence probes;PH value must be determined in aqueous phase
Method, it is characterised in that include following process:(a) chemical combination for representing above-mentioned logical formula (I), logical formula (II) or logical formula (III)
Thing and the process of hydrogen ion reaction, and the process that (b) determines the fluorescence intensity of the hydride-complex generated in above-mentioned operation;And
And the compound for representing above-mentioned logical formula (I), logical formula (II) or logical formula (III) is used as pH fluorescence probes.
The compound represented with above-mentioned formula (I), logical formula (II) or logical formula (III) is as manufacturing above-mentioned pH fluorescence
The intermediate of probe is useful.
In this specification, the moieties of " alkyl " or " alkoxy " refer to that such as carbon number is 1-10, preferably
The alkyl that straight chain, side chain, ring-type or their combinations that carbon number is 1-6, preferably carbon number 1-4 are formed.More specifically
Ground is said, is used as alkyl, preferably low alkyl group (alkyl that carbon number is 1-6).As low alkyl group, for example, it can include first
Base, ethyl, n-propyl, isopropyl, normal-butyl, sec-butyl, isobutyl group, the tert-butyl group, Cvclopropvlmethvl, n-pentyl, n-hexyl, ring
Hexyl etc..In this manual, in the case of having halogen atom, fluorine atom, chlorine atom, bromine atoms or iodine atom can,
It is preferred that fluorine atom or chlorine atom.
In the compound represented with above-mentioned formula (I), X is preferably CH=CH (i.e. with both sides phenyl ring formation talan
Structure) or do not have (i.e. with both sides phenyl ring formation biphenyl structural).In the compound represented with above-mentioned formula (I), preferably R1、
R2And R3One of be with formula (IA) represent group, two other be halogen atom, hydrogen atom, alkyl or alkoxy.R2In X tables
When the group contraposition shown, preferably R1And R3It is simultaneously halogen atom, hydrogen atom, alkyl or alkoxy.With formula (IA) table
In the group shown, m is preferably 0,1 or 2, R4Preferably alkyl, alkoxy or by formula (IB) represent group.In living cells radiography
In, R4The group preferably represented by formula (IB).For Y, preferably oxygen atom or nitrogen-atoms and the base represented with formula (IB)
Group's covalent bond and the group formed.It is preferred that when Y is oxygen atom, in the group represented with formula (IB), Z1And Z2Preferably oxygen is former
Son, preferably n and o are that 2, p is 1;It is preferred that when Y is nitrogen-atoms and the radicals covalent bonds represented with formula (IB) and the group formed,
R4It is preferred that formula (IB) represent group in, Z1And Z2Preferably oxygen atom, preferably n be 2, o be 1, p be contain in 0, Y use formula
(IB) in the group represented, Z1And Z2Preferably oxygen atom, Z3Do not have preferably, preferably n and o are that 2, p is 1. R5Preferably alkane
Base or alkoxy, in addition in the purposes of live cell fluorescent radiography, preferably R5For methoxyl group.
In the compound represented with above-mentioned (II) simultaneously, preferably R6And R7It is simultaneously methyl, R8It is methoxyl group.
In the compound represented with above-mentioned formula (III), preferably R9And R10It is simultaneously hydrogen atom, R11And R12For with formula
(IIIA) group represented.In preferred R11In the group represented for formula (IIIA), preferably r is that 2, s is that 1, t is 0, Z4And Z5It is excellent
Elect oxygen atom as;It is preferred that R12In the group represented for formula (IIIA), preferably r is that 2, s is that 1, t is 1, Z4、Z5And Z6Preferably
Oxygen atom;In the group that formula (IIIA) is represented, preferably R13For alkyl or alkoxy, in addition in live cell fluorescent radiography
In purposes, preferably R5For methoxyl group.It is preferred that X2For CH=CH (i.e. with both sides phenyl ring formation talan structure) or do not have (i.e.
With both sides phenyl ring formation biphenyl structural).
The compound of the invention represented with above-mentioned formula (I), (II) and (III) has with 1 according to the species of substituent
Individual or more than 2 asymmetric carbon atoms situation, be based not only on 1 or more than 2 asymmetric carbon atom optically active body or
Give any mixing of the stereoisomer and stereoisomer of the diastereoisomer of more than 2 asymmetric carbon atoms etc.
Thing, racemic modification etc. are intended to be included within.
Set out from the alpha-brominated acetophenone (HaI is halogen) of halo, by known references method (Angew. Chem.2012;
51(11):2673-6), via Dare shore reaction generation benzylamine, then with isonicotinic acid POCl3 backflow under conditions of clasp, shape
Into 4- (5- phenyl -2- oxazolyls) pyridine compounds of halo, further according to literature method, such as Suzuki and Heck reactions, and take
Phenyl boric acid or distyryl compound the formation biphenyl in generation (3,4 and No. 5 position) or the substitution of styrene group, that is, obtain part
Logical formula (I) product;Or, demethylation prepares the intermediate with hydroxyl on the basis of product, then carries out into ether, epoxy and adds
Into, Michael's conjugate addition reaction etc., obtain another part and lead to formula (I) product.
As the preferred embodiment to the logical formula (I), the preferable for leading to compound described in formula (II) and logical formula (III) embodies
Leading to the R in compound synthesis method described in formula (I) in substitution phenyl boric acid and substituted phenylethylene as described above2The otherness of group,
According to the substitution reaction with amido and the flexible chain of hydroxyl, logical formula (II) and (III) institute can be more prepared easily
The substitution phenyl boric acid and styrene intermediate needed, follow-up synthesis mode is with reference to logical formula (I), you can obtain logical formula (II) and formula
(III) compound.
In addition, in the embodiment of this specification, in more detail and it specifically show and record in this scenario exemplary
The manufacture method of compound.Thus, those skilled in the art according to these illustrate, suitably select reaction raw materials, reaction condition and
Reaction reagent etc., more needs, by the way that these synthetic methods are modified or changed, and can all manufacture above-mentioned formula table
The compound of the invention shown.
The exemplary compounds for meeting logical formula (I) structure are listed below:
The compound of the invention represented with above-mentioned formula (I), logical formula (II) and logical formula (III) is to have as fluorescence probe
Effect.The compound of the invention that is represented with above-mentioned formula (I), logical formula (II) and logical formula (III) and hydrionic complex compound
Photoluminescent property is varied widely compared with the photoluminescent property of itself, and their photoluminescent properties are complexed the difference of degree with hydrogen ion
Show regular change.Above-claimed cpd has larger dissolubility and has and specific can capture in aqueous
Hydrogen ion and the feature for forming complex compound.The complex compound of formation also has the feature that fluorescence is produced in cell living.Therefore, use
The compound of the invention that above-mentioned logical formula (I), logical formula (II) and logical formula (III) are represented is biological thin as determining in physiological conditions
The pH fluorescence probes of pH value in born of the same parents and biological tissue are exceedingly useful.In addition, so-called " measure " that is used in this specification
Belong to including qualitative and quantitative determination, it should make broadest explanation.
There is no particular limitation for the application method of the pH fluorescence probes of the present invention, can be same with known pH probes
Sample is used.Generally, it will be selected from and be dissolved in the aqueous mediums such as physiological saline or buffer solution or second with above-mentioned (I) compound represented
Immiscible material of the miscible organic solvents such as alcohol, acetone, ethylene glycol, dimethyl sulfoxide (DMSO), dimethylformamide and aqueous medium etc.
In, add the solution in the appropriate buffer solution containing cell and tissue, just can be with as long as determining its fluorescence emission spectrum.
【Brief description of the drawings】
Fig. 1:(a) uv-visible absorption spectra of the probe 1 in embodiment one in aqueous under various concentrations;(b) visit
The absorbance of the maximum absorption wave strong point of pin 1 with concentration situation of change.
Fig. 2:(a) uv-visible absorption spectra of the probe 2 in embodiment two in aqueous under various concentrations;(b) visit
The absorbance of the maximum absorption wave strong point of pin 2 with concentration situation of change.
Fig. 3:(a) uv-visible absorption spectra of the probe 3 in embodiment three in aqueous under various concentrations;(b) visit
The absorbance of the maximum absorption wave strong point of pin 3 with concentration situation of change.
Fig. 4:(a) uv-visible absorption spectra of the probe 4 in example IV in aqueous under various concentrations;(b) visit
The absorbance of the maximum absorption wave strong point of pin 4 with concentration situation of change.
Fig. 5:Probe 1 in embodiment one in the aqueous solution of the different pH value of in vitro with various Action of Metal Ions
Fluorescence column diagram.
Fig. 6:Fluorescence spectrum of the middle probe 1 of embodiment one in the different pH value aqueous solution;Insertion figure:Probe 1 is in pH 2.0-
Fluorescence intensity ratio I in the range of 5.5405/I450With the change curve of pH value.
Fig. 7:Fluorescence spectrum of the middle probe 2 of embodiment two in the different pH value aqueous solution;Insertion figure:Probe 2 is in pH 3.0-
Fluorescence intensity ratio I in the range of 4.0390/I520With the change curve of pH value.
Fig. 8:Fluorescence spectrum of the three kinds of probes 3 of embodiment in the different pH value aqueous solution;Insertion figure:Probe 3 is in pH 2.4-
In the range of 6.0 at 500nm fluorescence intensity and pH value change curve.
Fig. 9:Fluorescence spectrum of the example IV kind probe 4 in the different pH value aqueous solution;Insertion figure:Probe 4 is in pH 2.0-
In the range of 5.17 at 450nm fluorescence intensity and pH value change curve.
Figure 10:Fluorescent images of the middle probe 1 of embodiment one in Hela cells living;(a) with pH=6.6 lemon
Acid buffer culture 30min fluorescence picture;(d) bright field image of (a);(b) with pH=4 citrate buffer solution culture 30min's
Fluorescence picture;(e) bright field image of (b);(c) with pH=3 citrate buffer solution culture 30min fluorescence picture;(f) light field of (c)
Picture.
Figure 11:Fluorescent images of the middle probe 2 of embodiment two in Hela cells living.
Figure 12:Fluorescent images of the middle probe 3 of embodiment three in Hela cells living.
Figure 13:Fluorescent images of the example IV middle probe 4 in Hela cells living.
【Embodiment】
Embodiment one:Probe Probe 1 synthesis
It is raw material from triethylene glycol monomethyl ether, according to literature method, by three steps, is readily apparent compound 3, is brown
Color thick liquid nano product.Yield 79.9%.1H NMR(400MHz,CDCl3, δppm):7.14 (t, J=7.8Hz, 2H), 7.01
(d, J=8.9Hz, 4H), 6.92 (d, J=7.9Hz, 2H), 6.84 (s, 1H), 6.82 (d, J=8.9Hz, 4H), 4.11-4.08
(m, 4H), 3.85-3.82 (m, 4H), 3.73 (dd, J=5.9,3.5Hz, 4H), 3.69-3.63 (m, 8H), 3.55 (dd, J=
5.6,3.6Hz,4H),3.37 (s,6H).
In 250mL round-bottomed flask, DMF (1.15g, 16mmol) is added, at 0 DEG C (ice-water bath)
Under conditions of with syringe inject POCl3 (2.5g, 16mmol), stirring reaction 1h, by intermediate 3 (3.6g, 11mmol)
It is dissolved in 100mL chloroforms, adds reaction system, be warming up to 100 DEG C, react 5h, reaction is cooled to room temperature after terminating, will
Reactant is poured into frozen water, in the 20%NaOH aqueous solution and pH to 7, to be extracted with dichloromethane (50mL × 3), anhydrous sodium sulfate
Dry, filtering is evaporated removing solvent, with ethyl acetate/petroleum ether (2:1) as solvent, chemical combination is obtained through silica gel column chromatography
Thing 4 (2.8g).Faint yellow viscous product.Yield 48.8%.1H NMR(400 MHz,CDCl3,δppm):9.75(s,1H),7.62
(d, J=8.5Hz, 2H), 7.11 (d, J=8.7Hz, 4H), 6.90 (d, J=8.7Hz, 4H), 6.84 (d, J=8.4Hz, 2H),
4.13 (t, J=4.3Hz, 4H), 3.87 (t, J=4.8Hz, 4H), 3.76-3.73 (m, 4H), 3.71-3.65 (m, 8H),
3.57-3.53(m,4H), 3.38(s,6H).
In 250mL single-necked flasks, intermediate 3 (4.6g, 11mmol), N- bromo-succinimides are sequentially added
(1.96g, 11mmol) and 50mL DMFs, are stirred at room temperature reaction 4h.Frozen water is added, ethyl acetate is used
Extraction, anhydrous sodium sulfate drying, filtering revolves solvent evaporated, with ethyl acetate/petroleum ether (1:1) as solvent, through silicagel column
Chromatography obtains compound 5 (2.2g).Weak yellow liquid product.Yield 30.9%.1H NMR(400MHz,CDCl3,δppm):7.26-
7.18 (m, 2H), 7.00 (d, J=8.8Hz, 4H), 6.83 (d, J=8.8Hz, 4H), 6.78 (d, J=8.8Hz, 2H),
4.13-4.07(m,4H),3.87-3.82(m,4H),3.76-3.71(m,4H),3.71-3.63(m,8H),3.57- 3.54(m,
4H),3.38(s,6H).
In 500mL single-necked flasks, 2,4'- dibromos acetophenone (32.57g, 117.2mmol), six methines are sequentially added
Tetramine (16.5g, 117.9mmol) and 300mL chloroforms, stirring reaction 24h, filtering, smash filter cake to pieces, use three chloromethanes at room temperature
Alkane washing is multiple, takes solid phase to place vacuum drying oven and dries 12h, obtains 47.38g white solids.Extracting waste solid is in tri- mouthfuls of burnings of 500ml
In bottle, a glass three-way joint (joint connection nitrogen ball) is connect, flask is vacuumized with oil pump, nitrogen is then passed through by joint
Gas, is so repeated twice, and air in flask is removed as far as possible.It is dispersed in 200mL ethanol, is then stirring under the conditions of 0 DEG C
Mix down and add 150mL concentrated hydrochloric acids (injecting 10mL every time, be spaced 2min) by several times with syringe.Then stir anti-under the conditions of 0 DEG C
1h is answered, then is placed in room temperature reaction 24h.After reaction terminates, suction filtration removes white depositions, takes filtrate, is spin-dried for obtaining pale yellow colored solid
Body, is dried in a vacuum and obtains compound 6 (15.74g).Faint yellow solid.Yield 53.6%.1H NMR (400MHz,d6-
DMSO,δppm):8.51 (d, J=43.0Hz, 3H), 7.98 (d, J=8.4Hz, 2H), 7.83 (d, J=8.4Hz, 2H), 4.62
(d, J=5.3Hz, 2H)
In 500mL three-necked flasks, sequentially add intermediate 6 (15.74g, 62.7mmol) and isonicotinic acid (11.75g,
95.5mmol), dried condenser pipe is connected, a glass three-way joint (joint connection nitrogen ball) is connect in the condensation mouth of pipe, with oil
Pump is vacuumized to flask, is then passed through nitrogen by joint, is so repeated twice, and air and moisture in flask are removed as far as possible.
POCl is added with syringe3(70mL), is warming up to reflux temperature reaction 6h.After reaction terminates, room temperature is cooled to, residue is rotated
POCl3.EtOH is added into flask:H2O=2:1 (v/v) mixing liquid, makes it be all dispersed in liquid, pours into
500mL beakers, are aided with NaHCO with mass ratio for the 20% NaOH aqueous solution3Neutralize solution pH to 10 or so, during note
Anticipate temperature control, temperature rise higher (30 DEG C -40 DEG C) when by beaker insert in frozen water cool.Extracted with dichloromethane (70mL × 3),
Merge organic phase, use anhydrous Na2SO4Dry and then filter, collect filtrate, crude product, crude product post layer are obtained after filtrate is rotated
(eluant, eluent is the mixed solvent of ethyl acetate and petroleum ether to the purification of analysis method, and volume ratio is 1:3) compound 7 (1.20g) is obtained.It is light
Yellow solid product, yield 6.7%.1H NMR(400MHz,d6-DMSO,δppm):8.79 (d, J=5.9Hz, 2H), 8.03 (s,
1H), (d, J=8.5Hz, the 2H) of 8.01 (dd, J=4.7,1.3Hz, 2H), 7.85 (d, J=8.5Hz, 2H), 7.73
In 100mL three-necked flasks, sequentially add intermediate 9 (60mg, 0.20mmol), molecule QS- 1 (90mg,
0.15mmol), Anhydrous potassium carbonate (70mg, 0.51mmol), methyl tricapryl ammonium chloride (0.4mL) and 25mL N, N- dimethyl
Formamide, connects dried condenser pipe, a glass three-way joint (joint connection nitrogen ball) is connect in the condensation mouth of pipe, with oil pump pair
Flask is vacuumized, and is then passed through nitrogen by joint, is so repeated twice, and encasing flask with masking foil ensures lucifuge condition, fast
Speed weighs double (triphenylphosphine) palladium chlorides (30mg, 0.043mmol), pours into flask rapidly, flask is taken out very with oil pump
Sky, is passed through nitrogen by joint, is so repeated twice.160 DEG C are heated to, 24h is reacted, is cooled to room temperature, vacuum distillation is removed
Most of DMF is removed, (eluant, eluent is ethyl acetate) is purified with column chromatography and obtains probe 1 (80.0mg).Palm fibre
Brown viscous oily liquid.Yield 65.6%.1H NMR(400MHz,CDCl3,δppm):8.67 (d, J=4.7Hz, 2H), 7.86
(d, J=5.8Hz, 2H), 7.61 (d, J=8.3Hz, 2H), 7.47 (d, J=8.4Hz, 2H), 7.42 (s, 1H), 7.26 (d, J
=8.6Hz, 2H), 7.02 (d, J=16.3Hz, 1H), 6.97 (d, J=8.9Hz, 4H), 6.86 (d, J=16.7Hz, 1H),
6.82 (d, J=8.6Hz, 2H), 6.77 (d, J=8.9Hz, 4H), 4.07-3.98 (m, 4H), 3.80-3.74 (m, 4H), 3.67
(dd, J=5.8,3.4Hz, 4H), 3.64-3.55 (m, 8H), 3.48 (dd, J=5.6,3.6Hz, 4H), 3.30 (s, 6H)
.HRMS(M+H)for C48H53N3O9:816.3860 (calculated),816.3866(experimental);(M+Na)for
C48H53N3O9:838.3680 (calculated),838.3675(experimental)。
Embodiment two:Probe probe 2 synthesis
In 250mL single-necked flasks, intermediate 3 (4.6g, 11mmol), N- bromo-succinimides are sequentially added
(1.96g, 11mmol) and 50mL DMFs, are stirred at room temperature reaction 4h.Frozen water is added, ethyl acetate is used
Extraction, anhydrous sodium sulfate drying, filtering revolves solvent evaporated, with ethyl acetate/petroleum ether (1:1) as solvent, through silicagel column
Chromatography obtains probe 1 (2.2g).Weak yellow liquid product.Yield 30.9%.1H NMR(400MHz,CDCl3,δppm):7.26-
7.18 (m, 2H), 7.00 (d, J=8.8Hz, 4H), 6.83 (d, J=8.8Hz, 4H), 6.78 (d, J=8.8Hz, 2H), 4.13-
4.07(m,4H),3.87-3.82(m,4H),3.76-3.71(m,4H),3.71-3.63(m,8H),3.57-3.54 (m,4H),
3.38(s,6H).
In 100mL single-necked flasks, the tetrahydrofuran for taking 50mL to dry dissolves intermediate 8 (2.0g, 3.1mmol) and will
It adds flask, and system temperature is down into -78 DEG C, and n-butyllithium solution (8mL, 2.5M) is added under nitrogen protection, stirs 2h,
Add triisopropyl borate ester (0.88g, 4.7mmol), stirring reaction 8h.After reaction terminates, reaction solution is poured into 100mL frozen water,
It is acidity to add hydrochloric acid guarantee system, is extracted with dichloromethane, and revolving removes solvent, obtains crude product.Use ethyl acetate/methanol
(20:1) as solvent, compound 9 (1.3g) is obtained through silica gel column chromatography.Light yellow viscous liquid.Yield 68.8%.1H
NMR(400MHz,d6-DMSO,δppm):7.76 (s, 2H), 7.59 (d, J=8.5Hz, 2H), 7.01 (d, J=8.9Hz, 4H),
6.92 (d, J=9.0Hz, 4H), 6.68 (d, J=8.5Hz, 2H), 4.08-4.04 (m, 4H), 3.77-3.69 (m, 4H), 3.59
(dd, J=5.8,3.2Hz, 4H), 3.56-3.50 (m, 8H), 3.43 (dd, J=5.8,3.6Hz, 4H), 3.23 (s, 6H)
In 100mL three-necked flasks, compound 7 (200mg, 0.67mmol), compound 9 (400mg, 0.67mmol), nothing
Aqueous carbonate potassium (300mg, 2.2mmol), methyl tricapryl ammonium chloride (0.4mL), toluene, second and water each 7.5mL, 4.5mL and
1.5mL.The dried condenser pipe of connection, connects a glass three-way joint (joint connection nitrogen ball), with oil pump pair in the condensation mouth of pipe
Flask is vacuumized, and is then passed through nitrogen by joint, is so repeated twice, and encasing flask with masking foil ensures lucifuge condition, fast
Speed weighs tetrakis triphenylphosphine palladium (30mg, 0.026mmol), pours into flask rapidly, flask is vacuumized with oil pump, by connecing
Head is passed through nitrogen, is so repeated twice.100 DEG C are heated to, 24h is reacted, is cooled to room temperature, reaction solution is poured into 100mL water
In, extracted with acetic acid ethyl ester, revolving organic phase removes solvent, obtains crude product.With ethyl acetate/petroleum ether (3:1) as exhibition
Agent is opened, post is walked and obtains probe 2 (280mg).Light yellow viscous liquid.Yield 52.8%.1H NMR(400MHz,d6- DMSO,
δppm):8.78 (dd, J=4.6,1.5Hz, 2H), 8.01 (dd, J=4.6,1.5Hz, 2H), 7.98 (s, 1H), 7.92 (d, J=
8.4Hz, 2H), 7.76 (d, J=8.5Hz, 2H), 7.59 (d, J=8.7Hz, 2H), 7.05 (d, J=8.9Hz, 4H), 6.95
(d, J=9.0Hz, 4H), 6.85 (d, J=8.7Hz, 2H), 4.11- 4.05 (m, 4H), 3.77-3.71 (m, 4H), 3.59 (dd,
J=5.9,3.2Hz, 4H), 3.57-3.50 (m, 8H), 3.45-3.41 (m, 4H), 3.24 (s, 6H) .HRMS (M+H) for
C46H51N3O9:790.3703 (calculated),790.3705(experimental);(M+Na)for C46H51N3O9:
812.3523 (calculated),812.3519(experimental)。
Embodiment three:Probe probe 3 synthesis
With the identical synthetic method of above-described embodiment one, with 3,5- dimethyl -4- hydroxy benzaldehydes for raw material, probe 3 is obtained
(light yellow viscous liquid).Yield 66.0%.
1H NMR(400MHz,CDCl3,δppm):8.76 (d, J=6.0Hz, 2H), 8.02-7.89 (m, 2H), 7.74-
7.68(m,2H),7.60-7.54(m,2H),7.52(s,1H),7.20(s,2H),7.12-6.96 (m,2H),4.01-3.94
(m,2H),3.90-3.81(m,2H),3.79-3.75(m,2H),3.74-3.65(m, 4H),3.61-3.52(m,2H),3.41-
3.37 (m, 3H), 2.34 (d, J=11.2Hz, 6H) .HRMS (M+H) for C31H34N2O5:515.2546(calculated),
515.2549(experimental);(M+Na) for C31H34N2O5:537.2366(calculated),538.2363
(experimental)。
Example IV:Probe probe 4 synthesis
With the identical synthetic method of above-described embodiment two, with 2,5- dimethyl -4- bromophenols for raw material, probe 4 is obtained (yellowish
Color viscous oil-like liquid).Yield 90.1%.
1H NMR(400MHz,d6-DMSO,δppm):8.79 (d, J=5.5Hz, 2H), 8.02 (d, J=7.4Hz, 3H),
7.94 (d, J=8.2Hz, 2H), 7.78 (d, J=8.2Hz, 2H), 7.41 (s, 2H), 3.96- 3.89 (m, 2H), 3.77-3.71
(m,2H),3.66-3.60(m,2H),3.60-3.52(m,4H),3.48- 3.42(m,2H),3.25(s,3H),2.31(s,
6H).HRMS(M+H)for C29H32N2O5:489.2389 (calculated),489.2383(experimental);(M+Na)
for C29H32N2O5:512.2209 (calculated),512.2212(experimental)。
Embodiment five:Water solubility experiment
Using being obtained in the probe 3, embodiment three obtained in the probe 1, embodiment two obtained in above-described embodiment one
Probe 3 and example IV in obtained probe 4, its solvability is evaluated according to absorbance method.First respectively by probe 1,
Probe 2, probe 3 and probe 3, which are dissolved in match somebody with somebody in dimethyl sulfoxide, is prepared into 1.0 × 10-3M mother liquor, then progressively dilutes, and obtains one
The different mother liquor of series.Then it is added to by micro syringe in the quartz colorimetric utensil of the distilled water containing 3mL.In all situations
In, amount of the dimethyl sulfoxide in water is 0.2% (i.e. the probe molecule mother liquor of 6 μM of injection every time).It can so ensure that diformazan is sub-
The presence of sulfone does not interfere with dissolubility of the probe molecule in pure water.Probe 1, probe 2, the result of probe 3 and probe 4 are shown respectively
In Fig. 1, Fig. 2, Fig. 3 and Fig. 4.In figure, (a) figure represents the ultraviolet visible absorption spectra of corresponding compound under various concentrations;
(b) figure represents the absorbance of corresponding compound maximum absorption wave strong point with the situation of change of the concentration of corresponding compound,
For probe 1, probe 2, probe 3 and probe 4, this wavelength is respectively 413nm, 393nm, 358nm and 358nm.
The concentration of each (b) the figure linear region maximum into Fig. 4 of view 1 is solubility, probe 1, probe 2, the and of probe 3
Solubility of the probe 4 in water is respectively 30 μM, 20 μM, 13.3 μM and 13.3 μM.So there is flexible hydrophilic poly- second two
The compound of alcohol chain has very big solubility in aqueous, the pH value that is used to detect in aqueous environment for them and to work
Cell or the dyeing of biological tissue be very favorable.
Embodiment six:Ion selectivity is tested
Using the probe 1 obtained in above-described embodiment one, it is evaluated to hydrionic selectivity, 5 μM of probes 1 are distinguished
It is added to containing each metal ion species (25mM Na+, 5mM K+, Ca2+;0.1mM Mg2+, Mn2+, Fe2+, Ni2+, Pb2+, Cu2+, Cr2+)
Different pH value (pH be 6.6 or 3.0) the aqueous solution in, determine fluorescence emission spectrum.As a result it is shown in Fig. 5.
In figure, the longitudinal axis is probe 1 in different pH value and the aqueous solution containing different metal ions in emission spectra at 405nm
With the ratio of fluorescent emission intensity at 450nm.The probe 1 of the present invention has high selectivity to hydrogen ion, i.e. the probe pair
Hydrogen ion has extremely strong selectivity, even if the sodium ion largely existed in vivo, potassium ion, calcium ion, magnesium ion are with height
Under conditions of concentration is present, fluorescence intensity ratio value changes are also minimum.Alternatively, it is also possible to see other metal ions to the probe
The photoluminescent property of molecule influences also very little.
The compound of the present invention is using 4- (5- phenyl -2- oxazolyls) pyridines as protonation site, to hydrionic selection
Property should show similar property, be the pH probes of high selectivity.
Embodiment seven:Fluorescence titration is tested
The detection of probe 1, probe 2, probe 3 and probe 4 to pH value can pass through fluorescence titration experiment and its photoluminescent property
(it is the fluorescent emission intensity ratio at two wavelength for probe 1, is at a certain wavelength for probe 2, probe 3 and probe 4
Fluorescent emission intensity, this wavelength is near maximum emission wavelength) studied with the change curve of pH value, as a result it is shown in figure
6th, Fig. 7, Fig. 8 and Fig. 9.As a result show that probe 1 is suitable for detecting that pH scopes are the pH value in 3.5-4.4 environment.According to
Henderson-Hasselbatch Type equations (log [(Imax-I)/(I-Imin)]=pKa-pH), calculate probes probes 1
PKa value be 3.95;Probe 2 is suitable for detecting that pH scopes are the pH value under the conditions of 3.0-4.0 and its pKa value is 3.35;Probe
3 are suitable for detecting that pH scopes are the pH value under the conditions of 3.2-4.8 and its pKa value is 4.00;Probe 4 is suitable for detecting pH scopes
For the pH value under the conditions of 3.1-4.1 and its pKa value is 3.65.Thus, the photoluminescent property of compound of the invention is in a certain pH models
In enclosing, the change of regularity can be embodied with pH change, can be used for detecting the pH value under acid condition.
Embodiment eight:Living biological cells fluorescence imaging
The fluoroscopic visualization in living cells is carried out using above-mentioned probe 1, probe 2, probe 3 and probe 4.Hela cells are pressed
Cultivated according to regulation (ATCC, Manassas, VA, USA).Cell culture adds 10% in DMEM culture mediums in culture medium
FBS buffer solutions, add the units/ml of penicillin 100, the μ g/mL of streptomysin 100, in 37 DEG C of 5%CO2In incubator.Imaging two
Before it, Hela cells, which are seeded on the sterile cover slips in culture dish, to be made after its adherent 24h, removes non-attached cell.Experiment
Before the storing solution that concentration is 5mM is obtained with DMSO dissolvings probe Ai.Take 0.5 μ L probes (5mM, DMSO) to add respectively to contain
The culture medium (500 μ L) of attached cell makes its final concentration of 5 μM, is placed in 37 DEG C of 5%CO2 incubators and cultivates after 30min, uses
Citrate buffer (pH=6.6) is gently cleaned 3 times, to remove the probe for being introduced into cell excessive in culture medium.Will be thin
After born of the same parents' fixation under laser confocal microscope, pass through linear scan and carry out fluorescence photoimaging.
The living cells of above-mentioned probe 1, probe 2, probe 3 and probe 4 under the conditions of different pH value (6.6,4.0 and 3.0) is glimmering
Light figure is respectively as shown in Figure 10, Figure 11, Figure 12 and Figure 13.Cell sends blue-fluorescence, with the decline of pH value residing for cell,
The blue-fluorescence intensity sent shows obvious decrease, shows that pH change of the above-claimed cpd to living cells environment is very quick
Sense, so being very useful as the fluorescence probe of measure pH value.
It is emphasized that the above-mentioned embodiment enumerated only is some exemplary tests, limited examination is not considered as
Test or condition.The innovation scope that the present patent application is covered should be recorded by claims and is defined.
Claims (8)
1. a kind of compound, it is characterised in that the compound represented with following logical formula (I)s:
In formula, R1、R2And R3Separately represent halogen atom, hydrogen atom, alkyl, alkoxy or the base with following formula (IA)
Group
In formula, m represents 0,1 or 2, R4Represent hydrogen atom, alkyl, alkoxy or the group represented with following formula (IB);Y tables
Show the group for the formation that the group that methylene, oxygen atom or nitrogen-atoms and following formula (IB) are represented is connected
In formula, R5Represent hydrogen atom, alkyl or alkoxy;Z1、Z2And Z3Separately represent no or oxygen atom, n, o
0,1 or 2 are separately represented with p,
R1、R2And R3Can not be halogen atom, hydrogen atom, alkyl or alkoxy simultaneously;X represents CH=CH (i.e. with both sides phenyl ring shape
Into talan structure) or do not have (being biphenyl structural).
2. compound as claimed in claim 1, it is characterised in that the preferred mode of the logical formula (I), with 4- (5- phenyl -2-
Oxazolyl) pyridine is core texture, by diglycol chain by alkyl chain (R8-CH2-CH2-) and phenyl ring bonding, under
State the compound that logical formula (II) is represented:
In formula, R6And R7Separately represent halogen atom, hydrogen atom, alkyl or alkoxy;R8Represent hydrogen atom, alkyl
Or alkoxy;X1Represent CH=CH (i.e. with both sides phenyl ring formation talan structure) or do not have (being biphenyl structural).
3. compound as claimed in claim 1, it is characterised in that the preferred mode of the logical formula (I), with 4- (5- phenyl -2-
Oxazolyl) pyridine is core texture, introduces N in No. 4 positions of phenyl ring, the substituted amidos of N- bis- represent with following logical formula (III)s
Compound:
In formula, R9And R10Separately represent halogen atom, hydrogen atom, alkyl or alkoxy;X2Represent CH=CH (i.e. and both sides
Phenyl ring formation talan structure) or do not have (being biphenyl structural);R11And R12Separately represent hydrogen atom, alkyl,
Alkoxy or the group represented with following formula (IIIA)
In formula, R13Represent hydrogen atom, alkyl or alkoxy;Z4、Z5And Z6Separately represent no or oxygen atom, r, s
Separately represented with t 0,1 or 2, q represent 1 or 2.
4. a kind of prepare the method for leading to compound shown in formula (I) described in claim 1, it is characterised in that the alpha-brominated benzene of halo
Ethyl ketone (HaI is halogen) sets out, by known references method (Angew.Chem.2012;51(11):2673-6), via Dare shore
Reaction generation benzylamine, then with isonicotinic acid POCl3 backflow under conditions of clasp, formed halo 4- (5- phenyl -2- oxazoles
Base) pyridine compounds,
Reacted further according to such as Suzuki and Heck, and substitution (3,4 and No. 5 position) phenyl boric acid or distyryl compound formation connection
The substitution of benzene or styrene group, that is, obtain partial Formula (I) product;
Or, demethylation prepares the intermediate with hydroxyl on the basis of product, then carries out into ether, epoxy addition, mikey
Your conjugate addition reaction etc., obtains another part and leads to formula (I) product.
The preferred embodiment of the logical formula (I), the preferable of compound is embodied in described in logical formula (II) and logical formula (III) leads to as described above
Replace the R in phenyl boric acid and substituted phenylethylene in formula (I) the compound synthesis method2The otherness of group, according to amine
The substitution reaction of the flexible chain of base and hydroxyl, the substituted benzene needed for logical formula (II) and (III) can be more prepared easily
Boric acid and styrene intermediate, follow-up synthesis mode is with reference to logical formula (I), you can obtain the chemical combination of logical formula (II) and logical formula (III)
Thing.
5. a kind of application for the compound recorded containing claim 1-3 any one claim, it is characterised in that for pH
Fluorescence probe.
6. application as claimed in claim 5, it is characterised in that be applied particularly in aqueous phase (in vitro living biological cell, in vitro life
In thing living tissue, living biological cell or biopsy) measure of pH value.
7. application as claimed in claim 6, it is characterised in that
The assay method, including following process:
(a) compound that claim 1-3 any one claim is recorded and the process that hydrogen ion reacts are made, and
(b) process for determining the fluorescence intensity of the hydride-complex generated in above-mentioned operation.
8. application as claimed in claim 5, the compound that claim 1-3 any one claim is recorded is used as pH fluorescence
Application in fluorescence imaging detection of the probe in vitro living cells or in vitro biopsy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710187200.6A CN107011336B (en) | 2017-03-27 | 2017-03-27 | PH fluorescent probe with pyridine as protonation site and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710187200.6A CN107011336B (en) | 2017-03-27 | 2017-03-27 | PH fluorescent probe with pyridine as protonation site and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107011336A true CN107011336A (en) | 2017-08-04 |
CN107011336B CN107011336B (en) | 2020-08-14 |
Family
ID=59446519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710187200.6A Expired - Fee Related CN107011336B (en) | 2017-03-27 | 2017-03-27 | PH fluorescent probe with pyridine as protonation site and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107011336B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038659A1 (en) * | 2005-09-26 | 2007-04-05 | Invitrogen Corporation | Violet laser excitable dyes and their method of use |
CN103102232A (en) * | 2011-11-10 | 2013-05-15 | 三星显示有限公司 | Styryl-based compound, composition containing styryl-based compound, and organic light emitting diode including styryl-based compound |
CN105810837A (en) * | 2015-01-16 | 2016-07-27 | 三星显示有限公司 | Organic light-emitting device |
CN106083816A (en) * | 2016-07-06 | 2016-11-09 | 山西大学 | A kind of extremely acid carbazoles pH fluorescent probe and its preparation method and application |
-
2017
- 2017-03-27 CN CN201710187200.6A patent/CN107011336B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038659A1 (en) * | 2005-09-26 | 2007-04-05 | Invitrogen Corporation | Violet laser excitable dyes and their method of use |
CN103102232A (en) * | 2011-11-10 | 2013-05-15 | 三星显示有限公司 | Styryl-based compound, composition containing styryl-based compound, and organic light emitting diode including styryl-based compound |
CN105810837A (en) * | 2015-01-16 | 2016-07-27 | 三星显示有限公司 | Organic light-emitting device |
CN106083816A (en) * | 2016-07-06 | 2016-11-09 | 山西大学 | A kind of extremely acid carbazoles pH fluorescent probe and its preparation method and application |
Non-Patent Citations (7)
Title |
---|
HEE JUNG PARK,ET AL.: "Measurement of pH values in human tissues by two-photon microscopy", 《ANGEWANDTE CHEMIE》 * |
J. HERBERT HALL, ET AL.: "Syntheses and photophysical properties of some 5(2)-aryl-2(5)-(4-pyridyl)oxazoles and related oxadiazoles and furans", 《 J. HETEROCYCLIC. CHEM.》 * |
J. HERBERT HALL, ET AL.: "Syntheses and photophysical properties of some 5(2)-aryl-2(5)-(4-pyridyl)oxazoles and related oxadiazoles and furans", 《J. HETEROCYCLIC. CHEM.》 * |
S. I. DRUZHININ, ET AL.: "Excited state proton transfer in 2-heteroaryloxazoles. The principle of least photochemical motion", 《CHEMICAL PHYSICS》 * |
SANDRINE CHARIER. ET AL.: "Photophysics of a series of efficient fluorescent pH probes for dual-emission-wavelength measurements in aqueous solutions", 《CHEMISTRY-A EUROPEAN JOURNAL》 * |
付鲸铭: "一种含吡啶环的pH荧光探针的设计与应用", 《中国化学会第30届学术年会摘要集-第二十七分会:光化学》 * |
尹志刚: "《材料纵横》", 31 October 2013, 河南科学技术出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN107011336B (en) | 2020-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108822019B (en) | Polar fluorescence probe of a kind of detection fat drips and its preparation method and application | |
CN106946773B (en) | Ratio type two-photon formaldehyde fluorescent probe and preparation method and application thereof | |
CN102127055B (en) | Single-photon and two-photon homocysteine fluorescent probes and use thereof | |
Wang et al. | Novel NIR fluorescent probe with dual models for sensitively and selectively monitoring and imaging Cys in living cells and mice | |
CN104945322B (en) | Detect the compound and preparation method thereof of tumor hypoxia | |
CN110862819B (en) | PH fluorescent probe based on near-infrared fluorescent dye and preparation method and application thereof | |
CN108997195A (en) | A kind of two-photon viscosity probe and its preparation method and application positioning fat drips | |
CN112939957A (en) | Benzoindole derivative In-XY1, and synthesis method and application thereof | |
CN112062755B (en) | Near-infrared fluorescent molecular probe for detecting aspartyl aminopeptidase, preparation method and application | |
CN109563082A (en) | Magnetic resonance imaging compound, wherein mesosome, magnetic resonance imaging agent and application and magnetic resonance imaging method employing | |
CN110117229A (en) | Fluorescent probe and the preparation method and application thereof | |
CN105566207A (en) | Two-photon deep red emission fluorescent probe for imaging cell membranes in tissues based on molecular rotors | |
CN109369636A (en) | A kind of two-photon fluorescence probe and its preparation method and application for distinguishing different viscosities | |
CN105985769A (en) | Preparation and application of fluorescent probe for phiophenol | |
CN107118206A (en) | The pyridine derivate Zn of one class quinoline two2+Fluorescence probe and its application | |
CN107011336A (en) | One class is using pyridine as the pH fluorescence probes and its application for protonating site | |
CN105968064A (en) | Bis(m-methylphenyl) tetrazine dicarboxamide compound as well as preparation and application thereof | |
CN102702221B (en) | Xyloketal B analogue as well as preparation method and application thereof | |
CN107118760B (en) | A kind of pH fluorescence probe in the diproton site containing pyridine and morpholine group, preparation method and application | |
CN111072650B (en) | Benzothiazole hydrogen sulfide fluorescent probe | |
CN108690033A (en) | The fluorescence probe and its preparation method and application of the molecule of pharmaceutical activity containing flavonoids | |
CN108290841A (en) | Has fluorescent Retinoid X Receptor associativity molecule and application thereof | |
CN110483547A (en) | Simple phenols conjugate, synthetic method and the application of dihydroartemisinine | |
JP7157438B2 (en) | Reactive drug with acrolein, its use and novel compound | |
CN105601675B (en) | The synthesis of a kind of phosphorescent iridium complex and its fluorescent marker for imago of blood fluke |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200814 |
|
CF01 | Termination of patent right due to non-payment of annual fee |